文献速递临床试验与 GCP

机器人辅助全直肠系膜切除术对比腹腔镜辅助全直肠系膜切除术治疗中低位直肠癌的括约肌间切除术率研究:多中心随机临床试验研究方案

A study of intersphincteric resection rate following robotic-assisted total mesorectal excision versus laparoscopic-assisted total mesorectal excision for patients with middle and low rectal cancer: study protocol for a multicenter randomized clinical trial.
PubMed 文献 · Trials · 2024-10-21

本研究为多中心、优效性随机对照试验,旨在比较机器人辅助全直肠系膜切除术(RATME)与腹腔镜辅助全直肠系膜切除术(LATME)在中低位直肠癌患者中的括约肌间切除术(ISR)率。主要终点为ISR率,次要终点包括结肠肛管吻合率、中转开腹手术、中转经肛全直肠系膜切除术、腹会阴联合切除术率、术后30天内并发症和死亡率、病理结局、长期生存结局、功能结局和生活质量。

要点

  • 多中心优效性随机对照试验比较RATME与LATME在中低位直肠癌中的ISR率。
  • 主要终点为ISR率,次要终点涵盖吻合率、中转手术、并发症、病理、生存、功能及生活质量。
  • 将通过集中照片审核和半年一次评估确保质量与安全。

核心结论

  • 本试验将明确RATME是否提高中低位直肠癌患者的ISR率并促进肛门保留。
  • 本试验将为中低位直肠癌患者RATME与LATME在提高操作安全性方面的最佳治疗策略提供证据。

研究设计与样本

  • 多中心、优效性、随机对照试验,比较RATME与LATME在中低位直肠癌患者中的应用。
  • 主要终点为ISR率;次要终点包括结肠肛管吻合(CAA)率、中转开腹手术、中转经肛全直肠系膜切除术(TaTME)、腹会阴联合切除术(APR)率、术后30天内并发症和死亡率、病理结局、长期生存结局、功能结局和生活质量。
  • 将进行集中照片审核和半年一次评估等测量以确保质量与安全。
  • 试验注册号:ClinicalTrials.gov NCT06105203,注册日期2023年10月27日。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Robotic-assisted complete mesorectal excision (RATME) is increasingly being used by colorectal surgeons. Most surgeons consider RATME a safe method, and believe it can facilitate total mesorectal excision (TME) in rectal cancer, and may potentially have advantages over intersphincteric resection (ISR) and anus preservation. Therefore, this trial was designed to investigate whether RATME has technical advantages and can increase the ISR rate compared with laparoscopic-assisted TME (LATME) in patients with middle and low rectal cancer. METHODS AND ANALYSIS: This is a multicenter, superiority, randomized controlled trial designed to compare RATME and LATME in middle and low rectal cancer. The primary endpoint is the ISR rate. The secondary endpoints are coloanal anastomosis (CAA) rate, conversion to open surgery, conversion to transanal TME (TaTME), abdominoperineal resection (APR) rate, postoperative morbidity and mortality within 30 days, pathological outcomes, long-term survival outcomes, functional outcomes, and quality of life. In addition, certain measurements will be conducted to ensure quality and safety, including centralized photography review and semiannual assessment. DISCUSSION: This trial will clarify if RATME improves ISR and promotes anus preservation in patients with mid- and low-rectal cancer. Furthermore, this trial will provide evidence on the optimal treatment strategies for RATME and LATME in patients with mid- and low-rectal cancer regarding improved operational safety. TRIAL REGISTRATION: ClinicalTrials.gov NCT06105203. Registered on October 27, 2023.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Guo Y, He L, Tong W, et al. A study of intersphincteric resection rate following robotic-assisted total mesorectal excision versus laparoscopic-assisted total mesorectal excision for patients with middle and low rectal cancer: study protocol for a multicenter randomized clinical trial. Trials. 2024. PMID: 39434171. doi:10.1186/s13063-024-08561-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。